WHEREAS, Amgen wishes Kite, and Kite accepts, to perform preclinical development activities up to the filing of an investigational new drug application (“IND ”) of certain cell-based therapy products selected pursuant to the terms and conditions of the Agreement. WHEREAS, Amgen possesses research, development, manufacturing and commercialization expertise for the development and commercialization of pharmaceutical and biologics products in the field of oncology. WHEREAS, Kite is a biopharmaceutical company developing a novel generation of cell-based therapies to treat cancer. Kite and Amgen are sometimes referred to herein individually as a “ Party” and collectively as the “ Parties”. This RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “ Agreement”) is entered into as of Decem(the “ Signing Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“ Amgen”), and KITE PHARMA, INC., a Delaware corporation having an address at 2225 Colorado Avenue, Santa Monica, California 90404 (“ Kite”). RESEARCH COLLABORATION AND LICENSE AGREEMENT INTELLECTUAL PROPERTY AND PATENT RIGHTSĩ.4 Defense and Settlement of Third Party Claimsĩ.6 Kite Discussions regarding Third Party Intellectual Propertyġ2.4 Relationship to the Confidentiality Agreementġ5.2 Section 365(n) of the Bankruptcy Codeġ5.9 Sale Transaction or Amgen Acquisitionġ5.10 Sale Transaction or Kite Acquisition DEVELOPMENT AND COMMERCIAL MATTERSĪRTICLE 9. PRECLINICAL DEVELOPMENT ACTIVITIESģ.3 Amgen Expansion Option Additional TargetsĪRTICLE 7.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |